- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00437086
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
A Prospective Open-Label Pilot Trial of PS-341 (Bortezomib; VELCADE) for the Therapy of Symptomatic Advanced Myeloproliferative Disorders
RATIONALE: Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the abnormal cells.
PURPOSE: This clinical trial is studying the side effects and how well bortezomib works in treating patients with advanced myeloproliferative disorders.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the efficacy of bortezomib in patients with symptomatic advanced myeloproliferative disorders (i.e., myelofibrosis with myeloid metaplasia, chronic myelomonocytic leukemia, or FIP1LI-PDGFRA-negative mast cell disease).
- Determine the safety of this drug when administered on a modified schedule in these patients.
Secondary
- Determine the effect of this drug on bone marrow cellularity, tryptase-positive mast cells, reticulin fibrosis, osteosclerosis, and angiogenesis in responding patients
OUTLINE: This is a prospective, open-label, pilot, multicenter study. Patients are stratified according to disease (systemic mast cell disease vs chronic myelomonocytic leukemia vs myelofibrosis with myeloid metaplasia).
Patients receive bortezomib IV weekly for 4 weeks. Treatment repeats every 5 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a response (complete remission, partial remission, or minimal remission) after 2 courses may receive an additional 6 courses of therapy. Patients who achieve stable disease with acceptable toxicities after 2 courses receive bortezomib IV at a higher dose twice weekly for 2 weeks. Treatment with a higher dose of bortezomib repeats every 3 weeks for up to 6 courses.
Patients who are responders undergo bone marrow aspirate or biopsy and peripheral blood collection for evaluation of bone marrow cellularity, tryptase-positive mast cells, reticulin fibrosis, osteosclerosis, and angiogenesis by fluorescent in situ hybridization (FISH), immunohistochemistry, and other immunological laboratory methods.
After completion of study therapy, patients are followed periodically for up to 3 years.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- M. D. Anderson Cancer Center at University of Texas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed advanced myeloproliferative disorder, including 1 of the following subtypes:
Myelofibrosis with myeloid metaplasia defined by the following criteria:
Evaluable or symptomatic disease as evidenced by ≥ 1 of the following:
- Anemia, defined as hemoglobin < 10 g/dL OR erythrocyte-transfusion dependence, defined as requiring 1 transfusion within the past 8 weeks
- Symptomatic palpable splenomegaly (palpable hepatomegaly is acceptable if previously splenectomized) requiring treatment* NOTE: *Subjective but painful enough to mandate intervention
Chronic myelomonocytic leukemia (CMML) defined by the following criteria:
- Absence of an imatinib mesylate-sensitive molecular abnormality for CMML (i.e., t[5;12], t[5;10], t[1;5], and t[5;7]) confirmed by fluorescent in situ hybridization (FISH) or standard cytogenetic bone marrow analysis within the past 18 months
Symptomatic disease as evidenced by ≥ 1 of the following:
- Anemia, defined as hemoglobin < 10 g/dL OR erythrocyte-transfusion dependence, defined as requiring 1 transfusion within the past 8 weeks
- Palpable splenomegaly (palpable hepatomegaly is acceptable if previously splenectomized) requiring treatment* NOTE: *Subjective but painful enough to mandate intervention
- Leukocytosis associated with ascites, serositis, pleural effusions, vasculitis, or other overt manifestation
Systemic mast cell disease defined by the following criteria:
- Absence of the FIP1LI-PDGFRA mutation as confirmed by FISH
- Evaluable and symptomatic disease requiring therapy, as evidenced by involvement with organs other than skin (i.e., heart, bowel, peripheral blood, liver/spleen, or marrow)
- Debilitating mast cell mediator symptoms not responsive to standard therapy such as antihistamines
- Absence of t(9;22) translocation as confirmed by FISH or standard cytogenetic peripheral blood or marrow analysis at any prior time point
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Not incarcerated in a municipal, county, state, or federal prison
- Absolute neutrophil count ≥ 1,000/mm³
- Platelet count ≥ 75,000/mm³
- Creatinine ≤ 2.0 mg/dL
- Total or direct bilirubin ≤ 2.0 mg/dL
- AST and ALT ≤ 3 times upper limit of normal (unless clinically attributed to hepatic extramedullary hematopoiesis)
- No baseline peripheral or autonomic neuropathy ≥ grade 2
- No other condition or laboratory abnormality that would place the patient at unacceptable risk or confound the ability to interpret study data
- No hypersensitivity to boron, mannitol, or bortezomib
- No myocardial infarction within the past 6 months
- No New York Hospital Association class III-IV heart failure
- No uncontrolled angina
- No severe uncontrolled ventricular arrhythmia
No evidence of acute ischemia or active conduction system abnormality by ECG
- ECG screening abnormalities must be documented as not medically relevant
- No other serious medical or psychiatric illness that would preclude study participation
PRIOR CONCURRENT THERAPY:
- At least 14 days since prior chemotherapy (e.g., interferon alfa, anagrelide, or other myelosuppressive agent) or any other experimental therapy
- At least 14 days since prior growth factors
- At least 14 days since prior systemic use of corticosteroids
- More than 14 days since prior investigational drugs
- Concurrent hydroxyurea allowed for ≤ 14 days during study therapy if clinically indicated for extreme leukocytosis control
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PS-341
Designed to assess the toxicity and pilot response of PS-341 in patients with advanced myeloproliferative diseases.
|
1.6 mg/m2 by IV; 4 out of 5 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and severity of toxicities as assessed by NCI CTCAE v3.0
Time Frame: 40 weeks
|
40 weeks
|
Proportion of patients who show treatment success, as defined by anemia, spleen, bone marrow, or constitutional symptoms' response (complete, partial, major, or minor response)
Time Frame: 40 weeks
|
40 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effects of treatment, in terms of changes in bone marrow cellularity, tryptase-positive mast cells, reticulin fibrosis, osteosclerosis, and angiogenesis, in responding patients
Time Frame: 40 weeks
|
40 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000529906
- P30CA015083 (U.S. NIH Grant/Contract)
- MC0486 (OTHER: Mayo Clinic Cancer Center)
- 695-05 (OTHER: Mayo Clinic IRB)
- VEL-04-107 (OTHER: MPI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
Clinical Trials on PS-341
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.CompletedLeukemiaUnited States
-
Jules Bordet InstituteCompletedCarcinoma Breast Stage IVBelgium
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.CompletedLymphoma, B-CellUnited States
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerUnited States
-
Rasim GucalpMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung CancerUnited States
-
M.D. Anderson Cancer CenterCompletedMultiple MyelomaUnited States
-
Beijing Chao Yang HospitalEnrolling by invitationMultiple Myeloma | BortezomibChina
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedGraft-versus-Host DiseaseUnited States
-
University of ChicagoNational Cancer Institute (NCI)Completed
-
Children's Hospital Medical Center, CincinnatiCompletedAllogeneic Stem Cell Transplantation | Refractory Autoimmune Cytopenia(s)United States